Lipistad

Atorvastatin, the active ingredient in Lipistad, is a HMG‑CoA reductase inhibitor presented as an oral tablet for oral use. It lowers elevated LDL‑cholesterol and is used in hypercholesterolemia, mixed dyslipidemia, and for primary and secondary prevention of cardiovascular disease in adults. GNH USA supplies Lipistad as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lipistad (atorvastatin) acts on lipid metabolism to reduce cholesterol levels and associated cardiovascular risk. Hypercholesterolemia: lowers LDL‑cholesterol and total cholesterol. Primary prevention of cardiovascular disease: reduces risk of myocardial infarction and stroke in high‑risk patients. Secondary prevention of cardiovascular disease: helps prevent recurrent events after a cardiovascular incident. Mixed dyslipidemia: improves lipid profile when both cholesterol and triglycerides are elevated.

Adverse reactions may occur with atorvastatin therapy.

Common Side Effects: - Muscle aches or weakness. - Elevated liver enzymes (ALT, AST). - Gastrointestinal discomfort such as nausea or abdominal pain. - Headache. - Dizziness. - Fatigue.

Serious or Rare Side Effects: - Rhabdomyolysis leading to renal impairment. - Severe liver injury or hepatitis. - Acute pancreatitis. - Anaphylactic or severe allergic reactions. - Myopathy with marked CK elevation. - Thrombocytopenia.

Before initiating therapy, clinicians should evaluate liver function, assess cardiovascular risk, and review concomitant medications.

Assess liver function: obtain baseline ALT/AST and monitor periodically. Monitor lipid levels: check fasting lipid profile after 4‑6 weeks of therapy. Review concomitant medications: avoid drugs that increase atorvastatin exposure. Avoid in pregnancy: contraindicated for women who are pregnant or may become pregnant. Counsel on muscle symptoms: advise patients to report unexplained muscle pain or weakness. Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Atorvastatin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin). - Gemfibrozil or fenofibrate. - High‑dose niacin. - Certain antiretrovirals (e.g., protease inhibitors). - Cyclosporine.

Moderate Interactions (Monitor Closely): - Warfarin: monitor INR. - Digoxin: watch for increased serum levels. - Beta‑blockers: observe for additive hypotensive effects. - Other statins: assess for cumulative myopathy risk. - Certain antibiotics (e.g., erythromycin).